Oncimmune Holdings ( (GB:ONC) ) has provided an announcement.
Oncimmune Holdings Plc announced the successful passing of both resolutions at its Annual General Meeting held in London. The resolutions included the authority to allot shares and the disapplication of statutory pre-emption rights, both of which received overwhelming support from shareholders. This outcome reflects strong shareholder confidence and supports Oncimmune’s strategic initiatives in precision medicine, potentially enhancing its market positioning and operational capabilities.
More about Oncimmune Holdings
Oncimmune Holdings Plc is a precision medicine company that specializes in analyzing immune interactions through autoantibody profiles. The company partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for developing targeted therapies for immune-mediated diseases. Oncimmune’s mission is to enable precision medicine by discovering novel biomarkers, drug targets, and predicting treatment efficacy using their advanced technology platform. The company is headquartered in the UK, with facilities in Germany and business development teams in the US and Europe.
YTD Price Performance: -82.02%
Average Trading Volume: 328,441
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.88M
See more data about ONC stock on TipRanks’ Stock Analysis page.